1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66CF05E665F08D99000258D070042BDC8
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-impact-equation-demonstrating-strategic-impact-outcomes-data
18
19
20216.73.216.60
21
22
23www.emed24.net
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Affairs Excellence

The Medical Affairs Impact Equation: Demonstrating Strategic Impact Through Outcomes and Data

ID: 5894


Features:

13 Info Graphics

15 Data Graphics

290+ Metrics

12 Narratives


Pages/Slides: 35


Published: 2025


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “The Medical Affairs Impact Equation: Demonstrating Strategic Impact Through Outcomes and Data”

STUDY OVERVIEW

As Medical Affairs shifts from tactical execution to strategic leadership, the ability to demonstrate impact through outcomes and data has become a top priority. Organizations must move beyond activity metrics to show how Medical drives real-world change—whether through improved health outcomes, enhanced guideline concordance, or increased patient adoption.


This study examines how Medical Affairs teams measure strategic impact using lagging indicators and real-world data. It analyzes which outcomes are most valued, how they are linked to prior Medical activities, and what data sources are used to validate impact. The research also introduces frameworks for outcome measurement, explores data granularity across platforms, and identifies key hurdles in linking Medical tactics to strategic results.

KEY TOPICS

  • Lagging Indicators of Medical Impact
  • Real-World Data Outcomes
  • Linkability of Strategic Outcomes to Activities
  • Data Granularity and Source Utilization
  • Challenges in Outcome Measurement

KEY METRICS

  • Prioritizing strategic outcomes and assessing their linkability to medical activities
  • Measuring gaps between outcome importance and linkability
  • Trends in linking lagging indicators
  • Connecting real-world data and provider-level outcomes to tactical execution
  • Evaluating Medical’s role in launch readiness, guideline influence, and market access
  • Comparing perceived versus measured impact across lagging indicators
  • Key challenges in linking medical tactics to strategic outcomes
  • Adapting metrics to product lifecycle maturity—from launch to established brands
  • Updating measurement frameworks over time to align with evolving objectives
  • Balancing competing strategic priorities within Medical Affairs
  • Identifying critical data sources and optimizing data granularity to strengthen impact measurement

SAMPLE KEY FINDINGS

  • Top measurement hurdle hinges on too many market variables to clearly link action to outcome: 72% of surveyed Medical organization cite this is a major challenge. Meanwhile, 53% cite limited resources/data as a critical challenge, and 44% indicate “we don’t know what outcomes to measure.”
  • Managing leading and lagging indicators over time: Leading indicators are revisited monthly by 33% of organizations – more than any other interval surveyed. Lagging indicators are most often assessed on ad-hoc basis as needed (36% of orgs) or quarterly (33% of orgs).

METHODOLOGY

Best Practices, LLC conducted benchmarking with
40 Medical Affairs leaders from 30 leading biopharma companies. Interviews were also conducted with select participants to gather further insights on how Medical teams are demonstrating strategic impact through outcomes and data.

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Biopharmaceutical; Manufacturing; Consumer Products; Diagnostic; Health Care; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Alcon; Alnylam Pharmaceuticals; Amgen; Astellas Pharma; Azurity Pharmaceuticals; Bayer; Boehringer Ingelheim; CSL Vifor; EMD Serono; Eton Pharmaceuticals; Eurofarma; Gilead Sciences; Grifols; Jazz Pharmaceuticals; Johnson & Johnson; Merck & Co.; Novartis; Organon; Orphalan; Otsuka; Pacira BioSciences; QIAGEN; Sanofi; Santen Pharmaceutical; Scholar Rock; Stallergenes Greer; Supernus; Syndax Pharmaceuticals; Takeda

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.